Medical Journals

Mechanism of Action of the Microtubule-targeted Antimitotic Depsipeptide Tasidotin (Formerly Ilx651) and Its Major Metabolite Tasidotin C-carboxylate.

Authors:
  • Ray Anasuya
  • Okouneva Tatiana
  • Manna Tapas
  • Miller Herbert P
  • Schmid Steven
  • Arthaud Larry
  • Luduena Richard
  • Jordan Mary Ann
  • Wilson Leslie

From: Department of Molecular, Cellular, and Developmental Biology and the Neuroscience Research Institute, University of California-Santa Barbara, Santa Barbara, CA 93106, USA.

Cancer research

  • Publish Date: Apr 2007
  • ISSN: 0008-5472
  • Volume: 67
  • Issue: 8
  • Pages: 3767-76
  • Medium: Print
  • Language: English
  • Citation (JAMA): Ray Anasuya, Okouneva Tatiana, Manna Tapas, et al. Mechanism of Action of the Microtubule-targeted Antimitotic Depsipeptide Tasidotin (Formerly Ilx651) and Its Major Metabolite Tasidotin C-carboxylate.. Cancer Res. Apr 2007;67:3767-76

Abstract

Tasidotin (ILX-651), an orally active synthetic microtubule-targeted derivative of the marine depsipeptide dolastatin-15, is currently undergoing clinical evaluation for cancer treatment. Tasidotin inhibited proliferation of MCF7/GFP breast cancer cells with an IC(50) of 63 nmol/L and inhibited mitosis with an IC(50) of 72 nmol/L in the absence of detectable effects on spindle microtubule polymer mass. Tasidotin inhibited the polymerization of purified tubulin into microtubules weakly (IC(50) approximately 30 micromol/L). However, it strongly suppressed the dynamic instability behavior of the microtubules at their plus ends at concentrations approximately 5 to 10 times below those required to inhibit polymerization. Its major actions were to reduce the shortening rate, the switching frequency from growth to shortening (catastrophe frequency), and the fraction of time the microtubules grew. In contrast with all other microtubule-targeted drugs thus far examined that can inhibit polymerization, tasidotin did not inhibit the growth rate. In contrast to stabilizing plus ends, tasidotin enhanced microtubule dynamic instability at minus ends, increasing the shortening length, the fraction of time the microtubules shortened, and the catastrophe frequency and reducing the rescue frequency. Tasidotin C-carboxylate, the major intracellular metabolite of tasidotin, altered dynamic instability of purified microtubules in a qualitatively similar manner to tasidotin but was 10 to 30 times more potent. The results suggest that the principal mechanism by which tasidotin inhibits cell proliferation is by suppressing spindle microtubule dynamics. Tasidotin may be a relatively weak prodrug for the functionally active tasidotin C-carboxylate.

Mesh Headings (Keywords): Animals, Breast Neoplasms, Carboxylic Acids, Cattle, Cell Growth Processes, Cell Line, Tumor, Humans, Microtubules, Mitosis, Oligopeptides, Prodrugs


Check for Full Text / PubMed Unique Identifier (PMID): 17440090


This abstract is part of PubMed, a service of the U.S. National Library of Medicine. PubMed includes more than 17 million citations from MEDLINE and other life science journals for biomedical articles. See Copyright and Disclaimers.

Linked medical terms appearing on this page are added by Healia to help readers find more information and are not part of the original PubMed document.

The data herein was last updated on July 8th, 2008 and may not reflect the most current and accurate data available from NLM.


Advertisements

About | Privacy Policy | Business Solutions | Advertise | Contact | Add Healia to your site

©2012. Healia / Meredith Corporation  

Use of this site constitutes acceptance of our Terms of Service and Privacy Policy. All content on this Web site, including medical opinion and any other health-related information, is for informational purposes only and should not be used for a specific diagnosis or individual treatment plan for any situation. Use of this site and the information contained herein does not create a doctor-patient relationship. Always seek the direct advice of your doctor in connection with any questions or issues you may have regarding your own health or the health of others.